替莫唑胺在侵袭性垂体瘤及垂体腺癌中的治疗进展

Advances in the Treatment of Temozolomide in Aggressive Pituitary Tumors and Pituitary Adenocarcinoma

替莫唑胺(TMZ)是一种口服二代咪唑并四嗪类具有抗肿瘤活性的烷化剂,通过对DNA鸟嘌呤的甲基化来干扰基因转录而诱导DNA损伤,目前是治疗恶性胶质瘤的一线化疗药物。最近有关于TMZ治疗侵袭性垂体腺瘤及垂体癌的报道,有效率分别为60%和69%,且未发生明显并发症。O6-甲基鸟嘌呤-DNA转移酶(MGMT)的表达水平与其疗效呈负相关,从而可能干扰其疗效,由于目前缺乏对垂体癌及侵袭性垂体瘤的有效治疗手段,所以不应否认TMZ对此类患者的治疗有效性。TMZ对侵袭性垂体瘤及垂体癌的治疗机制及有效性仍需进一步探索。

Temozolomide（TMZ） is an oral second-generation imidazole and tetrazine with anti-tumor activity of alkylating agents.It interferes with gene transcription and DNA damage induced by methylation of DNA guanine.It is currently the first-line chemotherapy drugs treatment of malignant glioma.Recently,the TMZ treatment of invasive pituitary adenomas and pituitary cancer have been reported,and the efficiency respectively achieve 60% and 69% with no obvious complications occured.O6-methylguanine-DNA transferase（MGMT） expression levels and its efficacy is negatively correlated,which may interfere with its efficacy.Since the lack of an effective treatment for pituitary cancer and invasive pituitary adenoma at present,So TMZ effectiveness of the treatment of such patients should not be denied.TMZ on the mechanisms and effectiveness of the treatment of invasive pituitary adenoma and pituitary carcinoma requires further exploration.